Phase II study of bevacizumab in combination with carboplatin plus paclitaxel as first-line chemotherapy for non-squamous non-small cell lung cancer with malignant pleural effusion

被引：0
|
作者：
Tamiya, M. [1 ]
Tamiya, A. [2 ]
Asami, K. [2 ]
Okishio, K. [3 ]
Kawagchi, T. [2 ]
Suzuki, H. [1 ]
Okamoto, N. [1 ]
Kawase, I. [1 ]
Atagi, S. [3 ]
Hirashima, T. [1 ]
机构：
[1] Osaka Prefectural Hosp Org, Osaka Prefectural Med Ctr, Habikino, Japan
[2] Kinki Chuo Chest Med Ctr, Sakai, Osaka, Japan
[3] Kinki Chuo Chest Med Ctr, Clin Res Ctr, Sakai, Osaka, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3492
引用
收藏
页码：S826 / S826
页数：1
相关论文
共 50 条
  • [1] PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH CARBOPLATIN PLUS PACLITAXEL AS FIRST-LINE CHEMOTHERAPY FOR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITH MALIGNANT PLEURAL EFFUSION
    Tamiya, Akihiro
    Tamiya, Motohiro
    Yamadori, Tadahiro
    Yasue, Tomomi
    Nakao, Keiko
    Shiroyama, Takayuki
    Asami, Kazuhiro
    Morishita, Naoko
    Suzuki, Hidekazu
    Okamoto, Norio
    Okishio, Kyoichi
    Kawaguchi, Tomoya
    Hirashima, Tomonori
    Atagi, Shinji
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1159 - S1160
  • [2] Utility of atezolizumab plus bevacizumab, carboplatin, and paclitaxel combination for the treatment of advanced non-squamous non-small cell lung cancer patients with malignant pleural effusion
    Hisakane, Kakeru
    Atsumi, Kenichiro
    Seike, Masahiro
    Hirose, Takashi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (09)
  • [3] Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion
    Tamiya, Motohiro
    Tamiya, Akihiro
    Suzuki, Hidekazu
    Taniguchi, Yoshihiko
    Katayama, Kanako
    Minomo, Shojiro
    Nakao, Keiko
    Takeuchi, Naoko
    Matsuda, Yoshinobu
    Naito, Yujiro
    Shiroyama, Takayuki
    Okamoto, Norio
    Okishio, Kyoichi
    Kumagai, Toru
    Atagi, Shinji
    Imamura, Fumio
    Hirashima, Tomonori
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1106 - 1112
  • [4] A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer
    Ciuleanu, T.
    Tsai, C. -M.
    Tsao, C. -J.
    Milanowski, J.
    Amoroso, D.
    Heo, D. S.
    Groen, H. J. M.
    Szczesna, A.
    Chung, C. -Y.
    Chao, T. -Y.
    Middleton, G.
    Zeaiter, A.
    Klingelschmitt, G.
    Klughammer, B.
    Thatcher, N.
    LUNG CANCER, 2013, 82 (02) : 276 - 281
  • [5] Phase II study of bevacizumab (Bv) in combination with paclitaxel-carboplatin (PC) as first-line chemotherapy for nonsquamous (SQ) non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE).
    Tamiya, Motohiro
    Hirashima, Tomonori
    Tamiya, Akihiro
    Okamoto, Norio
    Suzuki, Hidekazu
    Yamadori, Tadahiro
    Morishita, Naoko
    Shiroyama, Takayuki
    Otsuka, Tomoyuki
    Kitai, Kanako
    Yasue, Tomomi
    Asami, Kazuhiro
    Minomo, Shojiro
    Sonobe, Syoko
    Nakao, Keiko
    Kawaguchi, Tomoya
    Atagi, Shinji
    Kawase, Ichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion
    Kitamura, Kazuhiro
    Kubota, Kaoru
    Ando, Masahiro
    Takahashi, Satoshi
    Nishijima, Nobuhiko
    Sugano, Teppei
    Toyokawa, Masaru
    Miwa, Koji
    Kosaihira, Seiji
    Noro, Rintaro
    Minegishi, Yuji
    Seike, Masahiro
    Yoshimura, Akinobu
    Gemma, Akihiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) : 457 - 461
  • [7] Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion
    Kazuhiro Kitamura
    Kaoru Kubota
    Masahiro Ando
    Satoshi Takahashi
    Nobuhiko Nishijima
    Teppei Sugano
    Masaru Toyokawa
    Koji Miwa
    Seiji Kosaihira
    Rintaro Noro
    Yuji Minegishi
    Masahiro Seike
    Akinobu Yoshimura
    Akihiko Gemma
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 457 - 461
  • [8] A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer patients with malignant pleural effusion
    Wu Di
    Cong Yue
    Zhang Ziran
    Zhang Jie
    Nie Jun
    Dai Ling
    Hu Weiheng
    Chen Xiaoling
    Ma Xiangjuan
    Tian Guangming
    Han Jindi
    Han Sen
    Wang Yang
    Long Jieran
    Fang Jian
    FUTURE ONCOLOGY, 2022, 18 (06) : 669 - 677
  • [9] Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion
    Motohiro Tamiya
    Akihiro Tamiya
    Hidekazu Suzuki
    Yoshihiko Taniguchi
    Kanako Katayama
    Shojiro Minomo
    Keiko Nakao
    Naoko Takeuchi
    Yoshinobu Matsuda
    Yujiro Naito
    Takayuki Shiroyama
    Norio Okamoto
    Kyoichi Okishio
    Toru Kumagai
    Shinji Atagi
    Fumio Imamura
    Tomonori Hirashima
    Investigational New Drugs, 2021, 39 : 1106 - 1112
  • [10] Phase2 study of bevacizumab with carboplatin–paclitaxel for non-small cell lung cancer with malignant pleural effusion
    Motohiro Tamiya
    Akihiro Tamiya
    Tadahiro Yamadori
    Keiko Nakao
    Kazuhiro Asami
    Tomomi Yasue
    Tomoyuki Otsuka
    Takayuki Shiroyama
    Naoko Morishita
    Hidekazu Suzuki
    Norio Okamoto
    Kyoichi Okishio
    Tomoya Kawaguchi
    Shinji Atagi
    Ichiro Kawase
    Tomonori Hirashima
    Medical Oncology, 2013, 30
12345